New Results
Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
Mesude Bicak, Katharina Lückerath, Teja Kalidindi, Sven-Erik Strand, Michael Morris, Caius Radu, Robert Damoiseaux, Norbert Peekhaus, Austin Ho, Darren Veach, Ann-Christin Malmborg Hager, Steven M Larson, Hans Lilja, Michael R McDevitt, View ORCID ProfileRobert J. Klein, David Ulmert
doi: https://doi.org/10.1101/754036
Mesude Bicak
1Icahn Institute for Data Science and Genome Technology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Katharina Lückerath
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
3Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
Teja Kalidindi
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Sven-Erik Strand
5Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Michael Morris
6Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Caius Radu
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
3Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
7Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
Robert Damoiseaux
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
Norbert Peekhaus
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
Austin Ho
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
Darren Veach
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
9Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
10Diaprost AB, Medicon Village, Lund, Sweden
Ann-Christin Malmborg Hager
10Diaprost AB, Medicon Village, Lund, Sweden
Steven M Larson
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
8Department of Radiology, Weill Cornell Medical College, New York, NY, USA
Hans Lilja
6Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
11Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
12Department of Translational Medicine, Lund University, Malmö, Sweden
13Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
14Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Michael R McDevitt
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
8Department of Radiology, Weill Cornell Medical College, New York, NY, USA
Robert J. Klein
1Icahn Institute for Data Science and Genome Technology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
David Ulmert
2University of California Los Angeles, Department of Molecular and Medical Pharmacology, Los Angeles, CA, USA
3Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
7Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, CA, USA
15Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA, USA
Article usage
Posted September 02, 2019.
Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
Mesude Bicak, Katharina Lückerath, Teja Kalidindi, Sven-Erik Strand, Michael Morris, Caius Radu, Robert Damoiseaux, Norbert Peekhaus, Austin Ho, Darren Veach, Ann-Christin Malmborg Hager, Steven M Larson, Hans Lilja, Michael R McDevitt, Robert J. Klein, David Ulmert
bioRxiv 754036; doi: https://doi.org/10.1101/754036
Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
Mesude Bicak, Katharina Lückerath, Teja Kalidindi, Sven-Erik Strand, Michael Morris, Caius Radu, Robert Damoiseaux, Norbert Peekhaus, Austin Ho, Darren Veach, Ann-Christin Malmborg Hager, Steven M Larson, Hans Lilja, Michael R McDevitt, Robert J. Klein, David Ulmert
bioRxiv 754036; doi: https://doi.org/10.1101/754036
Subject Area
Subject Areas
- Biochemistry (11715)
- Bioengineering (8723)
- Bioinformatics (29128)
- Biophysics (14935)
- Cancer Biology (12049)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14144)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12221)
- Genomics (16767)
- Immunology (11843)
- Microbiology (28014)
- Molecular Biology (11560)
- Neuroscience (60810)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10384)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)